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Background: The objective of this study is to assess the effectiveness of extracorporeal shock wave therapy in 
the management of calcifying tendinitis of the shoulder. Furthermore, a dose-response relationship was sought 
as a secondary conﬁ  rmation of effectiveness.
Hypothesis: Focused extracorporeal shock wave therapy has a high, dose-responsive effectiveness in the 
management of calcifying tendinitis of the shoulder.
Study Design: Meta-analysis.
Methods: Studies were identiﬁ  ed from online databases (MEDLINE, EMBASE, and Cochrane Controlled 
Trials Register), manual searches, and personal communication with experts in the ﬁ  eld. After assessment of 
heterogeneity, a random effects model was generated. The primary end points were identiﬁ  ed as pain and 
function by using the visual analog scale and the Constant-Murley Score, respectively. These end points were 
pooled and the weighted mean differences and 95% conﬁ  dence intervals were estimated. Odds ratios of the 
secondary end point deposit resorption were pooled.
Results: In 14 studies, shock wave therapy led to a signiﬁ  cantly higher reduction of pain (weighted mean 
difference, –2.8 points; 95% conﬁ  dence interval, –4.2 to –1.5 points) and improvement of function (weighted 
mean difference, 19.8 points; 95% conﬁ  dence interval, 13.4-26.3 points), compared to other treatments and 
placebo. High-energy treatment produced signiﬁ  cantly better results than low-energy treatment for pain 
reduction (weighted mean difference, 1.7 points; 95% conﬁ  dence interval, 0.7-2.6 points) and improvement of 
function (weighted mean difference, 10.7 points; 95% conﬁ  dence interval, 7.2-14.1 points). These results are 
consistent with a dose-response relationship supporting the effectiveness of shock wave therapy.
Conclusion: Shock wave therapy for calcifying tendinitis of the shoulder is effective in pain relief, function 
restoration, and deposit resorption; however, these conclusions are susceptible to bias arising from the 
limitations of the included studies.
Keywords: extracorporeal shock wave therapy; calcifying tendinitis; meta-analysis
C
alcifying tendinitis is a fairly common 
cause of shoulder pain. Estimates of the 
incidence rate of this disease range from 
2.5% to 20%.8 Its course may be self-limiting, but 
protracted suffering is not uncommon. Management 
usually is conservative, including subacromial 
injections, nonsteroidal anti-inﬂ  ammatory drugs, 
and physical therapy.8 Chronic and recalcitrant 
cases might need surgical treatment.12,19,23 Calcifying 
tendinitis of the shoulder is also frequently treated 
with extracorporeal shock wave therapy. The exact 
mechanisms of action are still elusive, but clinical 138
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results have been reassuring. There are a vast number 
of trials reporting on cohorts of patients undergoing 
this procedure; however, only a few controlled trials 
tested the effectiveness and safety of this procedure 
and its application is still somewhat controversial.
The primary objective of this study was to assess 
the effectiveness of shock wave therapy in calcifying 
tendinitis of the shoulder in comparison with a 
placebo or other treatments. The secondary research 
question was whether there is a dose-response 
relationship for high-energy versus low-energy shock 
wave therapy.
METHODS
This study was performed in accordance with the 
Quality of Reporting of Meta-Analysis (QUOROM) 
Statement and the Consolidated Standards of 
Reporting Trails (CONSORT) Statement (www.
consort-statement.org).14
The online databases MEDLINE, EMBASE, and 
the Cochrane Controlled Trials Register (CCTR) 
were searched without restrictions in language 
or publication date. The search string was 
“shoulder,” “wave,” and “tendinitis” or “tendinosis” 
or “tendonitis” or “tendonosis.” These terms were 
used as exploded keywords and medical subject 
headings (MeSH terms) where possible. Results 
were ﬁ  ltered for controlled trials using validated and 
highly sensitive strategies.20,24 Identiﬁ  ed studies were 
obtained and reviewed by 2 investigators 
(P.V. and J.H.) for inclusion. The references of 
included studies, as well as the “related article” 
function in PubMed, were used to search for 
additional studies. The authors also searched 
relevant journals by hand and interviewed experts 
in the ﬁ  eld to identify additional papers. The last 
search was performed in July 2008.
Study Selection
We included peer-reviewed articles reporting on 
controlled trials of shock wave therapy in the 
management of calcifying tendinitis of the shoulder. 
The diagnosis of calcifying tendinitis had to be 
conﬁ  rmed clinically and radiologically. The cutoff for 
high-energy and low-energy shock wave was set at 
0.2 mJ/mm2.
Trials comparing shock wave therapy with other 
treatments or sham treatment were included to 
answer this study’s primary question. Articles 
comparing shock wave therapy of different energy 
levels were included for the study’s secondary 
question. The internal validity of studies was 
classiﬁ  ed using the Jadad scale.10 This score attributes 
0 to 2 points for randomization and blinding and 0 or 
1 point for description of attrition.
Data Extraction and Analysis
Data extraction was duplicated independently 
by 2 investigators (P.V. and J.H.), using digital 
spreadsheets for the end points: reduction in pain, 
improvement of function, and deposit resorption. All 
end points were abstracted at, or as close as possible 
to, 6 months of follow-up. In case of incomplete 
description of study results, numbers were taken 
from graphs or the authors were contacted for 
clariﬁ  cation. After completion, these spreadsheets 
were cross-checked for mistakes and disagreement. 
Disagreement was resolved by consensus or this 
study’s senior author (R.D.) was consulted.
Data were analyzed separately concerning the 2 
study questions. Study heterogeneity was assessed 
using the Q test and quantiﬁ  ed by the I2 index. The 
Q test is a statistical method to test whether the 
individual study results are within a pooled 
estimate of all results (ie, are homogenous and all 
differences are due to random chance) or if they 
derive from a distribution around these pooled results 
(ie, are heterogeneous). This test depends 
on sample size, thus the threshold of signiﬁ  cance was 
set at P ≤ .1 to account for the test’s low 
power in small samples. In contrast to the 
sample-dependent, sizeless “yes/no” answer from the 
Q test, the I2 index gives a percent value of difference 
between studies beyond differences due to random 
chance. This percent value allows an investigator to 
judge the clinical importance of differences. To study 
possible sources of heterogeneity, subgroup analyses 
were done for high-energy and low-energy treatment 
and for different control groups (sham vs other 
treatment). Additionally, variables describing the 
studied populations (age and gender distribution), 
the provided treatment (absolute high-energy level, 
absolute low-energy level, ratio of energy levels, ratio 
of total energy administered, difference in energy 
levels, difference in total energy administered), and 
the precision of study estimates (standard errors of 
effect sizes) were tested for their association with 
absolute treatment effect and treatment effect size 
using forward stepwise multivariate meta-regression 
models, which apply multivariate regression to 
pooled estimates from meta-analyses to assess their 
role in between-study heterogeneity.
Data were pooled using the Cochrane Collaboration’s 
Review Manager (RevMan 4.2, Nordic Cochrane 
Centre, Copenhagen, Denmark). Weighted mean 
differences (WMDs) and 95% conﬁ  dence intervals 
(CIs) were calculated to pool continuous estimates 
for the end points. Weighted mean differences are the 139
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mean difference from all included studies multiplied 
by a parameter of the precision of the estimate of the 
individual studies. In this case, the inverse variance 
was used to account for differences in study size and 
precision of outcome assessment. Pooling was done 
using the DerSimonian-Laird random effects method, 
which is based on the assumption that the outcomes in 
the included studies are distributed around a common 
overall effect.5 Such models assume that the estimates 
of the individual studies are normally distributed 
around the pooled effect and can thus compensate 
for heterogeneity. For the binary outcome complete 
deposit resorption, the pooled odds ratio with 95% 
CI was calculated. Because in some groups there was 
no patient with complete resorption, 1 patient was 
added to all groups to allow for calculation of odds. 
Intercooled Stata 10 (StataCorp LP, College Station, 
Texas) was used to build regression models. An alpha 
level of 5% was considered signiﬁ  cant.
RESULTS
Fourteen studies were included in the quantitative 
data synthesis (Figure 1).ll All studies were published 
from 1998 to 2008 in German and English, reporting 
on a total of 995 patients (716 treated and 
279 controls). Tables 1 and 2 provide information 
Controlled trials identified from searches n = 94
(Medline n = 41
EMBASE n = 25
Cochrane Controlled Trials Register n = 25
Additional searches n = 3)
Trials retrieved for further evaluation
(n = 66 )  
Doubles excluded (n = 28)
Trials not focusing on shock
wave therapy, or the shoulder,
excluded (n = 51) 
Appropriate trials retrieved for further
analysis (n = 15) 
One Chinese trial could not be
obtained  (n = 1) 
Trials included in the meta-analysis (n = 14)
Figure 1. The ﬂ  ow of trials from searches to inclusion.
Table 1. Characteristics of the included studies.
                 High Energy Low Energy Controls
Study N Males:Females Age (Range) N Males:Females Age N Males:Females Age (Range)
Albert et al1 40 31:9 46.6 (31-64) 40 30:10 47.5 (32-69)
Buch et al2 15 8:7 56.2 15 9:6 49.9 15 11:4 52.5
Cacchio et al3 45 27:18 56.1 ± 1.9 45 28:17 56.4 ± 2.1
Cosentino et al4 35 20:15 51.8 35 23:12 51.8
Gerdesmeyer 
et al7
48 13:35 51.6 ± 8.5 48 16:32 47.3 ± 8.5 48 28:20 52.3 ± 9.8
Hsu et al9 33 15:18 54.4 (30-70) 13 4:9 57.8 (44-82)
Loew et al13 20 37.8% female 46 20 37.8% female 46 20 37.8% female 46
Pan et al15 32 12:20 55.2 ± 2.0 28 9:19 58 ± 1.83
Perlick et al16 40 55% female 48.4 (38-64) 40 55% female 48.4 (38-
64)
Peters et al17 31 19:12 52 ± 6 30 18:12 52 ± 6 29 18:11 52 ± 6
Pleiner et al18 23 8:15 54 ± 11 20 4:16 50 ± 8
Rompe et al21 50 25:25 49 50 31:19 47
Sabeti et al22 23 60% female 53.6 ± 8.8 21 60% female 49.4 ± 8.4
Wang et al26 37 14:23 51      6 3:3 53
llReferences 1-4, 7, 9, 13, 15-18, 21, 22, 26.140
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on basic parameters of patient demographics and 
treatments, respectively.
Using the Jadad scale, the overall quality of 
the studies was measured at a mean of 2.6 (95% 
CI,1.8-3.4), which is good compared to a study 
by Vavken et al25 of the average quality scores for 
orthopaedic studies. 
Shock Wave Treatment Versus Other 
Treatments
Hsu et al9 published the most recent trial in 2008, 
studying 33 patients treated with high-energy shock 
wave therapy and 13 receiving sham treatment. One 
major ﬂ  aw of this study was that the randomization 
sequence was based on the order of presentation of 
patients, thus not appropriately randomized, but also 
not blinded. This study showed signiﬁ  cantly better 
results in both pain reduction and improvement 
of function measured on the Constant-Murley 
score (CMS). Reduction of calcium deposits was 
signiﬁ  cantly better in the exposed group, but 
independent of Gaertner stage. The authors reported 
no signiﬁ  cant adverse effects with treatment.
A randomized trial of 60 patients receiving 
high-energy and low-energy shock wave therapy 
compared to treatment with a transcutaneous electric 
nerve stimulator (TENS) was published by Pan et al 
in 2003.15 Constant-Murley score, pain on a visual 
analog scale (VAS), and manual muscle tests were 
assessed at 2, 4, and 12 weeks. Deposit resorption 
was monitored with sonography at the same 
intervals. Shock wave treatment showed signiﬁ  cantly 
better results for pain, as well as higher rates of 
deposit resorption.
Cosentino et al4 conducted a single-blinded 
randomized study, with 70 patients undergoing 
either shock wave therapy or sham treatment.4 Pain 
and function were measured at 6 months using a 
VAS and CMS. Radiographs were used to assess 
deposit resorption. This study showed signiﬁ  cant 
improvements in pain and function for shoulders 
treated with shock wave therapy, as well as complete 
resorption of 31% of deposits.
Gerdesmeyer et al7 published the largest of the 
included studies in 2003. A total of 144 patients 
were allocated to either high-energy or low-energy 
shock wave therapy or placebo treatment in a 
randomized, double-blinded study. The primary 
end point was the 6-month CMS. Secondary 
end points were CMS at 3 months, pain at 6 
months, and radiographs at 3, 6, and 12 months. 
Ten patients were lost to follow-up. Signiﬁ  cant 
improvements in all end points were seen in both 
high-energy and low-energy groups compared to 
sham treatment 6 months after treatment, 
but signiﬁ  cantly better results were seen for 
high-energy treatment. The same pattern could be 
shown for 3 and 24 months of follow-up.
During the same year, Wang et al26 published the 
results from a prospective, blinded, nonrandomized 
trial of shock wave therapy versus sham treatment. 
However, most patients refused participation once 
allocated to sham treatment. Eventually, 33 patients 
received shock wave therapy, but only 6 patients 
were included in the control group. The CMS and 
pain on the VAS were recorded at 2 and 4 weeks, 3, 
6, and 12 months, and yearly thereafter. Signiﬁ  cantly 
more excellent and good results and a higher rate 
of deposit resorption in the exposed group were 
reported.
Buch et al2 reported on a prospective, controlled, 
but not randomized trial. Pain on the VAS, deposit 
resorption on radiography, subjective improvement, 
and the Roles and Maudsley score at 12 weeks 
were given for 15 patients allocated to high-energy, 
low-energy, or needling. Best, and persistent, results 
were shown for high-energy shock wave therapy, 
while the low-energy group had signiﬁ  cantly more 
recurrences. The needling group experienced higher 
rates of adverse effects.
High-Energy Versus Low-Energy Studies
In 2007, Albert et al1 used sample size calculations 
based on CMS and enrolled 80 patients in a 
blinded randomized trial of high-energy versus 
low-energy shock wave therapy on shoulder 
function. Secondary end points were change 
in intensity of self-rated shoulder pain and 
subjective success of treatment. In an intention-
to-treat analysis, high-energy treatment showed 
signiﬁ  cantly better results than low-energy 
treatment. Low-energy treatment produced no 
signiﬁ  cant improvement from the baseline value. 
The rates of deposit resorption over an average of 
110 days of follow-up were 15% and 5% for 
high-energy and low-energy treatment, 
respectively. Treatments were well accepted by all 
patients, although some petechiae or small bruises 
were reported in the high-energy group.
In 2006, Cacchio et al3 reported on a prospective, 
randomized, single-blinded trial of 90 patients 
treated with high-energy shock waves or sham 
treatment. Primary end points were improvement 
in the University of California at Los Angeles 
(UCLA) score or VAS pain scale at 6 months. The 
secondary end point was deposit resorption on 
plain radiographs, and attrition was considered 
in the ﬁ  nal analysis.3 This study found signiﬁ  cant 
reduction of pain and increases in function from 
4 weeks to 6 months of follow-up; 86.6% of 142
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all deposits in the treatment group completely 
resorbed by 6 months.
Sabeti et al22 published results of a blinded, 
randomized, controlled trial of high-energy versus 
low-energy shock wave therapy in 50 patients. 
Forty-four patients completed the study and showed 
signiﬁ  cant improvement in VAS and CMS scores, 
but no signiﬁ  cant differences were found between 
groups. This might be explained by the fact that both 
energy levels were low-energy treatments.
Pleiner et al18 performed a randomized, 
double-blinded study on 45 patients. Pain on VAS, 
improvement on the CMS, and radiologic deposit 
resorption were used as end points in 2 groups 
receiving either low-energy and high-energy intensity 
treatment.18 Seven months before ﬁ  nal analysis, 
10 patients (22%) were lost to follow-up, raising 
questions on the validity of this study. Throughout 
the duration of follow-up, the high-energy group 
showed signiﬁ  cantly higher CMS results, but better 
VAS results only during the ﬁ  rst week after treatment. 
At 7 months, 19% of the calciﬁ  cations in the 
high-energy group and 8% in the low-energy group 
were dissolved.
In the same year, Peters et al17 published the 
results from their randomized study on 90 patients 
receiving shock wave therapy on 2 energy levels and 
a placebo. Pain during treatment, symptoms, and 
deposit resorption were recorded at 6 months. The 
low-energy group had less pain during treatments, 
but needed more treatments and had more residual 
calciﬁ  cation than the high-energy group. Both 
treatment groups showed better results than the sham 
treatment.
Perlick et al16 included 80 patients in a blinded, 
randomized, controlled trial of high-energy versus 
low-energy shock wave treatment. Signiﬁ  cant 
increases in CMS were reported at 3 months after 
treatment but attenuation of this effect after 1 year. 
There were no signiﬁ  cant differences between 
groups, most likely due to the similar high-energy 
intensity exposure (0.23 and 0.42 mJ/mm2).
A trial of 80 patients in 4 groups receiving different 
levels of shock wave therapy or placebo treatment was 
published by Loew et al.13 End points (subjective, CMS, 
and deposit resorption at 3 months), showed signiﬁ  cant 
improvements in a dose-response–dependent manner 
for all end points.
The ﬁ  rst randomized, blinded study to be included 
in our analysis was performed by Rompe et al21 in 
1998. One hundred patients were allocated to either 
high-energy or low-energy treatment with end points 
measured at 24 weeks after treatment. Constant-Murley 
score, subjective rating, and plain radiographs were 
used. Both groups showed signiﬁ  cant improvement 
over time, but results were signiﬁ  cantly better for 
the high-energy group compared to the low-energy 
group.
Quantitative Data Synthesis
Data concerning this study’s primary research 
question from all eligible studies were assessed 
for heterogeneity by the Q test and the I2 index 
and showed 91.7% between-study variability for 
reduction of pain, 79.1% for improvement of 
function, and 66.1% for resorption of deposits. 
Graphical representation of the individual study 
estimates in forest plots revealed a more or less 
normal distribution of variability, thus the authors 
chose to employ a DerSimonian-Laird random effects 
model. For the second study question, there was 
clearly less, but still signiﬁ  cant, heterogeneity for 
reduction in pain (I2 = 61.2%) and improvement 
of function (I2 = 45.65). Again, the forest plots 
suggested a normal distribution of the effects of 
individual studies around a pooled estimate from a 
random effects model.
Before data were pooled, further assessment 
of potential sources of heterogeneity was done 
by analyzing subgroups by level of energy and 
type of control. The analysis showed only 
marginal reduction of the amount of between-
study variability for improvement of function. 
For reduction of pain, between-study heterogeneity 
was virtually eliminated in both high-energy 
subgroups, demonstrating this variable as a source of 
heterogeneity.
Concerning the primary study question, regression 
analysis of the effect sizes showed signiﬁ  cant positive 
associations with age (P = .002) and a negative 
association with percentage of females (P = .008), 
after Bonferroni adjustment for multiple testing. There 
was no signiﬁ  cant association with study precision 
as measured by standard errors of effects (P = .932). 
Concerning the second study question, a borderline 
signiﬁ  cant association was apparent between effect 
size and age (P = .056), but no associations of effect 
size with percentage of female patients, standard 
errors, or any variable describing differences in 
treatment regimens.
Concerning the primary question, a signiﬁ  cant 
result could be seen in pain reduction for high-
energy treatment levels versus other treatments 
with a WMD of –1.99 points and a 95% CI of –2.96 
to –1.03, and a WMD of –4.43 points and a 95% CI 
of –5.23 to –3.64 for high-energy versus placebo 
treatment. Low-energy treatment versus placebo 
treatment resulted in a WMD of –3.76 points and a 
95% CI of –6.57 to –0.96. There was no signiﬁ  cant 
difference in the reduction of pain after low-energy 143
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signiﬁ  cant associations between different treatment 
effects, between studies, and differences in age 
and percentage of female patients, thus suggesting 
this was a source of heterogeneity. Yet the most 
likely source of heterogeneity is differences 
within the treatments themselves—for example, 
some studies classify energy levels as high that 
are well below the low-energy levels classiﬁ  ed in 
others. What some consider an untreated control 
is a low-energy group for others. However, 
we could not ﬁ  nd associations between these 
differences and differences in outcomes for pain or 
function, leading to the conclusion that there is an 
independent, consistent dose-response relationship 
at all studied levels.
Finally, the graphical representation of the 
effects of the included studies suggested that these 
individual results were more or less normally 
distributed around, rather than forming clusters 
as would be expected in the case of 1 or more 
inﬂ  uential covariates. In the face of such a 
distribution of heterogeneity, pooling may be done 
using random effects models without jeopardizing 
the validity of results. However, we recommend 
cautiously interpreting all results and following the 
conﬁ  dence intervals rather than the absolute values 
of the mean differences.
The Jadad scale was used to assess the internal 
validity of the included trials, the results of which 
were encouragingly good. A potential downside of 
any method of quality assessment is not the quality 
of the study, but rather the quality of the reporting 
measured.6,11
Some studies might very well be considerably 
underpowered, thus showing spuriously insigniﬁ  cant 
results.
CONCLUSION
Shock wave therapy is a heterogeneous but effective 
treatment for calcifying tendinitis of the shoulder. 
One source of heterogeneity is patient selection, 
suggesting that not all patients beneﬁ  t equally. 
Currently, only ambiguous guidelines for the optimal 
number of sessions or impulses per session exist. 
These parameters did not appear to outweigh 
absolute energy levels in importance. Treatment 
effects may be substantially improved through 
addressing this problem.
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